Ghezzi Gioele, Falcidia Costanza, Paolino Giovanni, Mercuri Santo R, Narcisi Alessandra, Costanzo Antonio, Valenti Mario
Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.
Dermatol Ther (Heidelb). 2025 Apr;15(4):771-795. doi: 10.1007/s13555-025-01365-7. Epub 2025 Mar 10.
Chronic hand eczema (CHE) is a common and challenging skin condition, characterized by persistent hand dermatitis which lasts over 3 months or recurs at least twice a year. This condition is often multifactorial, involving genetic predispositions, environmental factors and triggers, such as irritants and allergens. Studies show a higher incidence in women, though prevalence estimates vary across different age groups. The pathogenesis involves complex immune mechanisms, particularly Th1/Th2 cell responses. Clinically, CHE presents in various forms, with symptoms such as redness, scaling and itching that significantly impact patients' quality of life. Treatment approaches are diverse. While emollients and topical corticosteroids have historically been the mainstay, new systemic therapies like JAK inhibitors and biologics are progressively being used for severe cases. Key molecular targets comprise interleukin (IL)-4 and IL-13, the JAK-STAT pathway, phosphodiesterase 4 (PDE4) and chemoattractant chemokines. Managing CHE effectively remains a challenge because of its chronicity and the variability in individual responses to treatment. However, emerging therapeutic strategies will help clinicians to offer more patient-centred approaches.
慢性手部湿疹(CHE)是一种常见且具有挑战性的皮肤疾病,其特征为持续性手部皮炎,病程超过3个月或每年至少复发两次。这种情况通常是多因素的,涉及遗传易感性、环境因素和触发因素,如刺激物和过敏原。研究表明女性发病率较高,不过不同年龄组的患病率估计有所不同。其发病机制涉及复杂的免疫机制,尤其是Th1/Th2细胞反应。临床上,CHE有多种表现形式,症状包括发红、脱屑和瘙痒,严重影响患者的生活质量。治疗方法多种多样。虽然润肤剂和外用糖皮质激素一直是主要治疗手段,但像JAK抑制剂和生物制剂等新的全身治疗方法正逐渐用于重症病例。关键分子靶点包括白细胞介素(IL)-4和IL-13、JAK-STAT途径、磷酸二酯酶4(PDE4)和趋化因子。由于其慢性病程以及个体对治疗反应的变异性,有效管理CHE仍然是一项挑战。然而,新兴的治疗策略将有助于临床医生提供更以患者为中心的治疗方法。